breast cancer bone metastases
Oncology · 2008–2008
2decisions
1medicine
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ibandronic acid Treatment of bone metastases from breast cancer. The submission sought a Restricted benefit listing for patients with bone metastases from breast cancer. | Mar 2008 | Not recommended | no section in document |
| ibandronic acid Treatment of bone metastases from breast cancer. Oral formulation providing a more convenient dosing option compared to intravenous administration. | Nov 2008 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.